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Evaluate Effect of VCD & Cross-flow on Protein Sieving
• A schematic of the experimental setup used for evaluation and the resulting differences in titer over time are shown in Figure 4A&B. 
• A reduced sieving profile was observed when the VCD target increased to 40E6 vc/ml (Figure 5).  An increase in ATF™2 cross-flow rate did not improve the reduced protein sieving trend (Figure 5B).
Results
Develop a LD Perfusion Cell Culture Process
• Initial studies successfully demonstrated application of a baseline perfusion process to Mobius 3L® single-use (SU) bioreactor and subsequent scalability to the Mobius ® 50L single-use bioreactor (Figure 1). 
• The implementation of bioreactor volume automation, reduced heating blanket size, and improved PID tuning improved process control variability (Figure 2A&B:  temperature example).
• Improved cell growth consistencies with durations of 30+ days were obtained in Mobius 3L® bioreactors using improved perfusion process (Figure 3).
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Summary
• Long-duration perfusion (30+ days) was 
successfully demonstrated in Mobius® 3L single-
use bioreactor.
• An increase in VCD resulted in decreased protein 
sieving.  Increased circulation flow did not improve 
the reduced protein sieving  trend.
• Consistent product quality over time was observed 
in long duration perfusion compared to fed-batch.
Materials & Methods
CHO cells expressing a therapeutic mAb were grown and 
expanded first in shake flasks until sufficient cell density for 
inoculation of the bioreactors. Mobius® 3L single-use bioreactors 
were used for perfusion and fed-batch runs with working volumes 
of 1.7L.  The ATF™ perfusion device was connected to the 
harvest line of the bioreactor.  Detailed process parameters for 
perfusion bioreactor runs are shown in Table 1.
Abstract
Perfusion processes have traditionally been used for the
generation of unstable proteins in cell culture systems. The use
of perfusion for production of stable proteins has been limited by
low product concentration, media costs, and system complexity.
However, with the advent of new single-use technology, cell
culture media specifically formulated to support high density
perfusion, and high-producing cell lines, perfusion processes are
gaining widespread industry attention. Additionally, perfusion
processes are considered an integral part of the “Factory of the
Future” (FOF) vision through enabling continuous processing
while delivering a product effluent with consistent product quality
and concentration.
In this study, we evaluate the ability of a long duration perfusion
process to deliver a consistent product stream. Although rarely
reported, a reduction in protein sieving/transport through the
microfiltration-based cell retention device is associated with
many perfusion processes. To better understand this
observation, we have investigated the impact viable cell density
(VCD) and cross-flow rate on protein sieving through a
microfiltration-based (MF) cell retention device connected to a
Mobius® 3L single-use bioreactor operated in a 30+ day
perfusion process. It has also been reported that perfusion
processes can be exploited to deliver a consistent product with
more uniform product quality attributes. To support this
observation, we also present product quality data (glycosylation
profiles) for a long duration mAb perfusion process and compare
the results to a more traditional fed-batch process.
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Purpose
• Develop a long duration (LD) perfusion cell culture process
• Evaluate effect of VCD and cross-flow rate on protein sieving
• Compare perfusion product consistency to fed-batch over 
time 
PROCESS VARIABLE VALUE
Mobius® Bioreactor 3L
Cell line CHO-S-C6
Cell Culture Media
CellVento™ CHO-100 + Methionine Sulfoximine                                   
+ Antifoam C (as needed)
Total Working Volume 1.7L
Agitation 250 rpm 
Temperature 36.8 °C 
pH 7.0 ± 0.05
Dissolved Oxygen 50%
Cell Retention Device ATF™2 System 
Circulation Rate 1.0-1.5 L/min
Hollow Fiber Cartridge 1mm lumen, 1300 cm2 
Table 1. Experimental Process Parameters
Figure 2A&B. Improved Temperature Control
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 Media bleed/refeeds clearly visible
 Significant cell debris burn-on 
 Tight temperature control (36.5±0.5C)
 No cell debris burn-on
Product Quality Consistency (Perfusion vs Fed-batch) 
• Glycosylation profiles obtained from the harvest stream of perfusion presented in Figure 6 are more consistent over time compared fed-batch (Figure 7). 
• For perfusion, equivalent glycosylation profiles were observed after VCD bleed target stabilized on Day 19. 
Figure 3. Long Duration Perfusion:  Improved Growth
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Figure 6. Perfusion: Glycosylation Species %
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Figure 1A&B. Mobius® 3L & 50L SU Bioreactor Scalability
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Figure 4A&4B.  Protein Sieving: Titer in Bioreactor and Harvest  
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 Protein Sieving = Harvest Titer/Bioreactor Titer
Figure 5A&B.  Protein Sieving: VCD and Cross-Flow
 3L Mobius® SU Bioreactor can support long duration perfusion runs
 35+ day perfusion run using ATF™2 system
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Figure 7A&B. Fed-Batch VCD & Glycosylation
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* Max cross-flow corresponded do 3400/s average wall shear rate.
*
Arrows indicate specific harvest stream sample points for product quality analysis in Figure 7.
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